<DOC>
	<DOC>NCT01617941</DOC>
	<brief_summary>It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.</brief_summary>
	<brief_title>A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Male and female smoking and nonsmoking subjects of 18 to 65 years of age (inclusive) Patients diagnosed with nonchronic migraine with or without aura of duration of at least 12 months prior to the study start Patient diagnosed with migraine (according to the International Headache Society categories 1.1 and with equal to/more than 3 and equal to/ less than 12 migraine attacks per 4 weeks for each of the last 6 months preceding the Screening Patients willing to abstain from activities that require focused attention, e.g. driving a car or other vehicles, operating machines or engaging in potentially dangerous activities that require focused attention and intact physical balance Patients diagnosed with basilar, ophthalmoplegic or hemiplegic migraine as shown in the current/past medical history. Patients having an experience of nonmigraine headaches on more than 6 days per 4 weeks in the past 6 months prior to study start Patients receiving regular treatment during the four (4) weeks preceding the Baseline with psychoactive drugs (e.g. hypnotics, benzodiazepines, neuroleptics) except antidepressants (eg. SSRIs, SNRIs, Tri or Tetracyclics). Patients receiving migraine prevention medications during past three (3) months preceding Baseline Patients receiving topiramate as migraine prevention medication during past six (6) months preceding Baseline Patients receiving metamizole as acute treatment of migraine during past three (3) months preceding Baseline Patients using (or having used within four (4) weeks before the treatment start) drug treatments that are potent inhibitors of OATP transporters (e.g. rifampin). Any psychiatric condition (e.g., schizophrenia, dementia, bipolar disorder) as shown in the past medical history prior to study start Patients with recent (within the last three [3] years prior to study start) and/or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting, palpitations, orthostatic hypotension etc.). Pregnant or nursing (lactating) women. Baselines (1 and 2). Patients with history of drug or alcohol abuse within the 12 months prior to dosing Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>non-chronic migraine, migraine prevention</keyword>
</DOC>